Related Experiment Video

Updated: Jul 26, 2025

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

37.8K

Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors

Zheng-Cheng Yu1,2,3, Tianhe Li1,2,3, Ellen Tully1,2,3

  • 1Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.

Cancer Research
|June 12, 2023
PubMed

Insights

ARID1A mutations in ovarian cancer impair DNA repair. Combining temozolomide with PARP inhibitors exploits this defect, causing synthetic lethality and suppressing tumor growth in preclinical models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • ARID1A, a SWI/SNF chromatin remodeler subunit, is frequently mutated in endometrial cancers, including ovarian and uterine clear cell carcinoma (CCC) and endometrioid carcinoma (EMCA).
  • Loss-of-function ARID1A mutations disrupt epigenetic regulation, cell-cycle control, and DNA damage repair pathways.
  • ARID1A-deficient cells accumulate DNA base lesions and abasic sites, indicating impaired base excision repair (BER).

Purpose of the Study:

  • To investigate the therapeutic potential of combining temozolomide (TMZ) with poly (ADP-ribose) polymerase inhibitors (PARPi) in ARID1A-mutated cancers.
  • To elucidate the underlying mechanisms of synthetic lethality induced by this drug combination.

Main Methods:

  • Assessment of DNA damage and repair kinetics in ARID1A-deficient cells.
  • Evaluation of the efficacy of TMZ and PARPi combination therapy in vitro and in vivo using ovarian cancer models.
  • Analysis of DNA double-strand breaks, replication stress, and apoptosis induction.

Main Results:

  • ARID1A deficiency leads to accumulated DNA base lesions and delayed BER.
  • While TMZ monotherapy was ineffective, the combination of TMZ and PARPi induced significant DNA double-strand breaks, replication stress, and replication fork instability in ARID1A-deficient cells.
  • The TMZ and PARPi combination potently inhibited the in vivo growth of ARID1A-mutated ovarian tumor xenografts, inducing apoptosis and replication stress.

Conclusions:

  • The combination of temozolomide and PARP inhibitors represents a promising synthetic lethal strategy for ARID1A-mutated cancers.
  • This approach exploits the specific DNA repair vulnerabilities in ARID1A-inactivated tumors to enhance therapeutic response.
  • Further clinical validation is warranted to explore the efficacy of this combination in patients.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K